Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A

Visterra

Status and phase: Completed; Phase 2

Conditions: Influenza A

Treatments: Drug: High dose of VIS410; Drug: Placebo; Drug: Low dose of VIS410

Study type: Interventional

Funder types: Industry

Identifiers

NCT03040141

VIS410-203

Details and patient eligibility

About

This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support.

Full description

This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support. Subjects will be followed for 56 days.

Enrollment: 89 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female subjects aged ≥ 18 years.

• Test positive for influenza A by rapid antigen test or with another commercially available test on an adequate nasopharyngeal specimen in accordance with the manufacturer's instructions, or an acceptable local test, including PCR (Polymerase chain reaction), FIA (Fluorescent immunoassay), or ELISA

• Onset of influenza symptoms no more than 5 days before VIS410/placebo infusion; symptoms may include cough, dyspnea, sore throat, fever, myalgias, headache, nasal symptoms (rhinorrhea, congestion), fatigue, diarrhea, anorexia, nausea, and vomiting.

• Requirement for oxygen support including any positive pressure ventilation

• Women of childbearing potential must have a negative pregnancy test within 2 days prior to VIS410/placebo infusion.

• Women should fulfill one of the following criteria:

  • Post-menopausal; either amenorrhea ≥ 12 months or follicle stimulating hormone > 40 mIU/mL as documented in their medical history
  • Surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation
  • Women of childbearing potential participating in heterosexual sexual relations must be willing to use adequate contraception from screening until 60 days post VIS410/placebo infusion.

• Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects who have a female partner of childbearing potential must use an effective birth control method from screening until 60 days post VIS410/placebo infusion.

• Subject, or a legally acceptable representative (LAR), is able to understand the purpose and risks of the study and willing to give voluntary written informed consent.

Exclusion criteria

• Known or suspected intolerance or hypersensitivity to VIS410, oseltamivir, pretreatment medications (diphenhydramine, or to both ibuprofen and acetylsalicylic acid [ASA]), or closely related compounds (eg, other monoclonal antibodies)
• Subjects who have received VIS410 in the past
• History of receiving monoclonal antibody products (including VIS410) within 3 months prior to VIS410/placebo dosing or planned administration during the study period
• Subjects who have taken more than 6 doses of an approved antiviral therapy for influenza within the prior 96 hours (eg, oral oseltamivir, inhaled zanamivir, IV peramivir, or oral ribavirin) between onset of symptoms and VIS410/placebo dosing
• Subjects with known co-infection with influenza B or other viral respiratory infections (e.g., respiratory syncytial virus, parainfluenza viruses, respiratory adenoviruses)
• Subjects with lung transplant or history of severe chronic lung disease, including cystic fibrosis or any condition requiring home oxygen therapy
• Subjects on extracorporeal membrane oxygenation (ECMO) at time of randomization
• Subjects with end stage renal disease who are not undergoing hemodialysis
• Subjects with active graft-vs-host disease, hematopoietic stem cell transplant within the previous 90 days, or human immunodeficiency virus infection with a CD4 cell count of less than 200 per cubic millimeter
• Hospitalization for > 48 hours prior to randomization
• High probability of mortality within 48 hours of randomization as determined by the Investigator
• Subjects weighing less than 45 kg
• Enrollment in any other investigational drug or device study, any disease or vaccine study within 30 days prior to Day 1 or within 5 half-lives of the investigational compound, whichever is longer
• Known or suspected alcohol or drug abuse, that is, abuse of a level that would compromise the safety or cooperation of the subject in the opinion of the Investigator

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

89 participants in 3 patient groups, including a placebo group

VIS410 low dose

Experimental group

Description:

Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir

Treatment:

Drug: Low dose of VIS410

VIS410 high dose

Experimental group

Description:

Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir

Treatment:

Drug: High dose of VIS410

Placebo

Placebo Comparator group

Description:

Single intravenous infusion of placebo in addition to oseltamivir

Treatment:

Drug: Placebo